Anticoagulation in COVID-19: a single-center retrospective study
Introduction: COVID-19 induces a pro-thrombotic state as evidenced by microvascular
thrombi in the renal and pulmonary vasculature. Therapeutic anticoagulation in COVID-19 …
thrombi in the renal and pulmonary vasculature. Therapeutic anticoagulation in COVID-19 …
[HTML][HTML] Occurrence of thromboembolic events and mortality among hospitalized coronavirus 2019 patients: large observational cohort study of electronic health …
AC Spyropoulos, JM Crawford, YWC Chen… - TH Open, 2022 - thieme-connect.com
Background Most symptoms of coronavirus 2019 (COVID-19) are mild; however, some
patients experience cardiovascular complications, including thromboembolic events and …
patients experience cardiovascular complications, including thromboembolic events and …
Anticoagulation strategy and safety in critically ill COVID-19 patients: a French retrospective multicentre study
P Lamouche-Wilquin, L Perrin, M Pere, M Raymond… - Thrombosis …, 2023 - Springer
Background Patients with critical illness due to COVID-19 exhibit increased coagulability
associated with a high risk of venous thrombo-embolism (VTE). Data on prophylactic …
associated with a high risk of venous thrombo-embolism (VTE). Data on prophylactic …
[HTML][HTML] Risk factors for systemic and venous thromboembolism, mortality and bleeding risks in 1125 patients with COVID-19: relationship with anticoagulation status
W Li, Z Xu, H Xiang, C Zhang, Y Guo, J Xiong - Aging (Albany NY), 2021 - ncbi.nlm.nih.gov
Aim: Coronavirus disease 2019 (COVID-19) has been associated with increased mortality
and morbidity from thromboembolism, especially venous thromboembolism. There are more …
and morbidity from thromboembolism, especially venous thromboembolism. There are more …
The COVID-19 pandemic: disproportionate thrombotic tendency and management recommendations
S Karim, A Islam, S Rafiq, I Laher - Tropical Medicine and Infectious …, 2021 - mdpi.com
COVID-19 is an infectious disease caused by the SARS COV-2 virus. Patients with COVID-
19 are susceptible to thrombosis due to excessive inflammation, platelet activation …
19 are susceptible to thrombosis due to excessive inflammation, platelet activation …
COVID-19 and thrombotic complications—the role of anticoagulants, antiplatelets and thrombolytics
G Khandelwal, A Ray, S Sethi… - Journal of Family …, 2021 - journals.lww.com
Abstract Coronavirus disease 2019 (COVID-19) is a global pandemic the world is dealing
with currently. Clinical evidences suggest that the patients are predisposed to both venous …
with currently. Clinical evidences suggest that the patients are predisposed to both venous …
A review of venous thromboembolism in COVID‐19: A clinical perspective
S Ozsu, E Gunay… - The clinical respiratory …, 2021 - Wiley Online Library
Abstract Coronavirus disease‐19 (COVID‐19) started in Wuhan, China in December 2019
and spread to all around the world in a short period of time. Hospitalized patients with …
and spread to all around the world in a short period of time. Hospitalized patients with …
Incidence, risk factors, and clinical impact of major bleeding in hospitalized patients with COVID-19: a sub-analysis of the CLOT-COVID Study
J Nakamura, I Tsujino, S Yachi, M Takeyama… - Thrombosis journal, 2022 - Springer
Background The coronavirus disease 2019 (COVID-19) causes extensive coagulopathy and
a potential benefit of anticoagulation therapy has been documented for prevention of …
a potential benefit of anticoagulation therapy has been documented for prevention of …
Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic
B Marchandot, A Trimaille, A Curtiaud… - Journal of Thrombosis …, 2020 - Springer
A common and potent consideration has recently entered the landscape of the novel
coronavirus disease of 2019 (COVID-19): venous thromboembolism (VTE). COVID-19 has …
coronavirus disease of 2019 (COVID-19): venous thromboembolism (VTE). COVID-19 has …
Antithrombotic therapy in patients with COVID-19?-Rationale and Evidence
In patients with severe or critical Coronavirus disease 2019 (COVID-19) manifestations, a
thromboinflammatory syndrome, with diffuse microvascular thrombosis, is increasingly …
thromboinflammatory syndrome, with diffuse microvascular thrombosis, is increasingly …